Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rong-Chung Lin

Urology Monroeville, PA Medical Doctor

NPI 1588774327 CMS profile 117052

2566 Haymaker Road, Pob #1 Room 306, Monroeville, PA 15146

Open in the dashboard

General payments

$2,058

109 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

3 holdings reported · through program year 2025

Through program year 2025, Rong-Chung Lin of Monroeville, PA is reported in the CMS Open Payments database as having received $2,058 across 109 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $122 4
2024 General $144 8
2023 General $325 17
2022 General $84 5
2021 General $253 15
2020 General $208 14
2019 General $922 46
2021 Ownership $0 1
2020 Ownership $0 1
2019 Ownership $0 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rong-Chung Lin
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Rong-Chung Lin were reported at $122. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Rong-Chung Lin Urology median Middle half National median
2019 $922 $480 $147–$1,201 $163
2020 $208 $246 $87–$645 $114
2021 $253 $358 $111–$1,000 $132
2022 $84 $476 $143–$1,263 $149
2023 $325 $560 $168–$1,461 $160
2024 $144 $563 $170–$1,464 $164
2025 $122 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $855 41 payments
  2. Pfizer Inc. $479 27 payments
  3. Sumitomo Pharma America, Inc. $279 18 payments
  4. Janssen Biotech, Inc. $155 7 payments
  5. Myovant Sciences Inc. $146 10 payments
  6. E.R. Squibb & Sons, L.L.C. $49 1 payment
  7. Merck Sharp & Dohme Corporation $31 1 payment
  8. Urovant Sciences Inc $22 1 payment
  9. PROCEPT BioRobotics Corporation $22 1 payment
  10. Aytu BioScience, Inc $11 1 payment
  11. Other $9 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,943 104 payments
  2. Education $115 5 payments
Products named General payments · program years 2019–2025
  1. XTANDI $917 56 payments
  2. GEMTESA $301 19 payments
  3. MYRBETRIQ $232 12 payments
  4. ERLEADA $164 8 payments
  5. ORGOVYX Hormone Therapy $146 10 payments
  6. ORGOVYX Oncology $82 5 payments
  7. OPDIVO $49 1 payment
  8. KEYTRUDA $31 1 payment
  9. PAXLOVID $27 2 payments
  10. AQUABEAM SYSTEM $22 1 payment
  11. Other $44 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,158

Median for Urology: 1,053

Drug cost

$198,841

Median for Urology: $101,464

Branded share of claims

35.1%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 58 $52,661
Gemtesa Vibegron Brand 65 $51,545
Eligard Leuprolide Acetate Brand 29 $38,987
Orgovyx Relugolix Brand 11 $29,316
Tamsulosin Hcl Generic 440 $8,254
Mirabegron Er Mirabegron Brand 11 $6,278
Oxybutynin Chloride Er Oxybutynin Chloride Brand 75 $1,964
Potassium Citrate Er Potassium Citrate Brand 20 $1,861
Trimethoprim Generic 31 $1,727
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 42 $1,688

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$43,095

Medicare's payments for the services billed

Medicare patients

206

Average age 75

Services billed

935

41 women, 165 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 39%
Diabetes 37%
Atrial fibrillation 27%
Chronic kidney disease 27%
Heart failure 20%
Depression 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTANDI
  • Astellas Pharma US Inc $69
$69 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $53
$53 65 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

109 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record